Completed from United Kingdom
I signed up for the Pharmacoeconomics course hoping to brush up on budgeting for new medicines, and it delivered. The lessons on budget impact analysis were spot‑on – I could immediately apply the template to a project at my NHS trust. The reading list was solid, especially the WHO guidelines that were easy to follow. I liked the relaxed style of the videos; they made complex concepts feel approachable. All in all, a useful course that helped me meet my learning objectives, even if I wish there were a few more interactive quizzes.
The Pharmacoeconomics course at Stanmore School of Business perfectly aligned with my professional goals. The modules on cost‑effectiveness analysis gave me a clear framework to evaluate new drug therapies, and the hands‑on Excel workbook allowed me to build my own incremental cost‑effectiveness ratio models. The case studies from real‑world pharmaceutical firms were especially relevant, helping me translate theory into actionable insights for my current role in market access. Overall, the material was up‑to‑date, the instructor’s explanations were concise, and I feel fully equipped to support pricing decisions.
Wow! This Pharmacoeconomics program blew me away. The instructor’s enthusiasm made every lecture feel like a fresh discovery. I learned to conduct health technology assessments from scratch and even built a Markov model for a cancer drug using the provided R scripts. The real‑world examples from Indian pharma companies helped me see exactly how to present cost‑utility results to senior management. The course materials were top‑notch – crisp slides, downloadable templates, and a vibrant forum where peers shared insights. I’m now confident to lead pharmacoeconomic evaluations at my organization.
The Pharmacoeconomics curriculum was exceptionally thorough. It began with foundational concepts such as willingness‑to‑pay thresholds before moving to detailed sections on sensitivity analysis and probabilistic modelling. I particularly appreciated the step‑by‑step guide on constructing a decision‑tree model in TreeAge, which I later used for a cost‑benefit study in a South African hospital setting. The supplemental reading material, including recent peer‑reviewed articles, ensured the content was current and relevant to emerging market challenges. The learning experience was rigorous yet supportive, and I left the course with a solid toolkit for evaluating drug value.
